Editor's Note: From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer research"
DOI: 10.1158/0008-5472.can-19-0502
Abstract: The editors are publishing this note to alert the readers to a concern about [this article][1] ([1][2]). The editors were made aware of apparent splicing between Western blot lanes 3 and 4 in Fig. 7B.… read more here.
Keywords: novel class; cyclooxygenase inhibitor; editor note; inhibitor celecoxib ... See more keywords
Expression of COX-2 and 15-PGDH in adenomas removed during pretreatment colonoscopy to predict chemopreventive efficacy of the selective COX-2 inhibitor, celecoxib.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.4_suppl.524
Abstract: 524Background: The APC trial showed that patients at high risk for colorectal adenoma development experienced a 33-45% reduction in post-polypectomy adenoma detection when treated with the selective cyclooxygenase-2 (cox-2) inhibitor, celecoxib. Unfortunately, this study also… read more here.
Keywords: inhibitor celecoxib; pgdh; cox; expression ... See more keywords